NCT02880163View on ClinicalTrials.gov

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

June 28, 2025

Study Completion Date

July 28, 2025

Conditions
Hemorrhagic ShockTraumaExsanguinating HemorrhageShock; Traumatic
Interventions
DEVICE

ResQFoam

Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma

Trial Locations (1)

45219

RECRUITING

University of Cincinnati, Cincinnati

Sponsors
All Listed Sponsors
lead

Arsenal Medical, Inc.

INDUSTRY

NCT02880163 - REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam | Biotech Hunter | Biotech Hunter